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EXPERIMENTAL
Peptides constitute a new group of promising drugs, with a diverse range of pharmacological activities. One of their most promising targets is the Central
Nervous System (CNS), where the Blood-Brain Barrier (BBB) constitutes an important flux-regulating compartment. In order to measure BBB transport influx 
constants, radiolabeld peptide tracers are used. However, it is reported that enzymatic degradation as well as deiodination occurs in vitro and in vivo [2, 3]. 
This phenomenon should be taken into account since the deiodinated metabolite(s) can cause the biologic activity. Therefore, the in vitro stability of different 
iodinated mouse obestatin derivatives is characterised in the main metabolic compartments: plasma, liver and kidney. 
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In-vitro metabolic stability
Peptides are incubated at 37°C in mice brain, plasma, liver and kidney
tissue homogenates using a mixing block heater. Aliquots are taken at 
suitable time points, and analyzed (after acidification, heating at 95°C and 
centrifugation) using HPLC. Results are expressed as half-life times, 
calculated from the regression curves.
Typical HPLC-UV conditions
Everest C18  238EV54 (250 × 4.6 mm, 300 Å, 5 µm) column (Grace Vydac) 
at 30°C, with (A) 0.1% formic acid in water, and (B) 0.1% formic acid in 
acetonitrile.  A gradient program was used and the flow rate was set at 1.0 
ml/min. Detection was permorded with PDA (190-400 nm).
I1Y mouse obestatin
T ½ (min)  EM-1 EM-2 CTAP 
Liver 13 18 225 
Brain 205 88 119 
Kidney 8 14 101 
Plasma 7 4   60 
 
Typical results are given here. For the BBB transport, only the results for EM-2 are given here, as the other peptides were successfully analyzed using the 
same methodology (data not given in this presentation).
Table 1: In-vitro metabolic stability half-lives
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Figure 1: Distribution between brain parenchyma and 
capillaries in the EM-2 brain influx experiment Figure 2: The efflux of EM-2 from brain.
Significant differences in the degradation kinetics of the iodinated peptides, arising from both enzymatic proteolysis and deiodination, were found when 
compared to the native, unmodified peptide. LC-MS/MS analysis demonstrated that the cleavage sites were dependent upon the biological matrix and the 
location of the amino acid residue incorporating the iodine atom(s). The degrading enzymes were found to target peptide bonds further away from the iodine 
incorporation, while proteolytic cleavages of nearby peptide bonds were inhibited. Di-iodinated amino acid residue containing peptides were found to be more 
susceptible to deiodination than the mono-iodinated derivative.
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